Biocryst Pharmaceuticals (BCRX) Share-based Compensation Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 10.06% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 9.14% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 0.43% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -8.13% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | -1.73% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -8.04% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 4.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.59% |
| Mar 31, 2026 | 4.59% |
| Dec 31, 2025 | 41.09% |
| Sep 30, 2025 | 81.05% |
| Jun 30, 2025 | -55.56% |
| Mar 31, 2025 | -47.99% |
| Dec 31, 2024 | 28.42% |
| Sep 30, 2024 | -33.33% |
| Jun 30, 2024 | -25.86% |
| Mar 31, 2024 | -24.59% |
| Dec 31, 2023 | 111.40% |
| Dec 31, 2022 | -115.28% |
| Sep 30, 2022 | -27.12% |
| Jun 30, 2022 | -30.36% |
| Mar 31, 2022 | 42.51% |
| Dec 31, 2021 | -136.62% |
| Sep 30, 2021 | 67.78% |
| Jun 30, 2021 | 60.57% |
| Mar 31, 2021 | -41.66% |
| Dec 31, 2020 | 36.51% |